Let the Biologics Begin

The FDA's Jan. 31 approval of Amevive (alefacept) for chronic plaque psoriasis represents the first step down an exciting new road, said Alan Menter, M.D, medical director of the Psoriasis Research Center at Baylor University Medical Center.

Related Videos
Related Content

Tips to Organize the Digital Chaos with Alina Bridges, DO

March 20th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Expert Tips on Alopecia Management From AAD 2023

March 20th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Treating Body Dysmorphic Disorder in Cosmetic Patients

March 20th 2023

Isotretinoin Best Practices: New Formulations, Avoiding Relapses, and More

March 20th 2023

Tips to Organize the Digital Chaos with Alina Bridges, DO

March 20th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Expert Tips on Alopecia Management From AAD 2023

March 20th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Treating Body Dysmorphic Disorder in Cosmetic Patients

March 20th 2023

Isotretinoin Best Practices: New Formulations, Avoiding Relapses, and More

March 20th 2023

Tips to Organize the Digital Chaos with Alina Bridges, DO

March 20th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Expert Tips on Alopecia Management From AAD 2023

March 20th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Treating Body Dysmorphic Disorder in Cosmetic Patients

March 20th 2023

Isotretinoin Best Practices: New Formulations, Avoiding Relapses, and More

March 20th 2023
© 2023 MJH Life Sciences

All rights reserved.